Article Versions Notes

Lee M-R, Huang H-L, Lin S-W, Cheng M-H, Lin Y-T, Chang S-Y, Yan B-S, Kuo C-H, Lu P-L, Wang J-Y, et al. Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. Journal of Clinical Medicine. 2019; 8(6):812. https://doi.org/10.3390/jcm8060812

Lee, Meng-Rui, Hung-Ling Huang, Shu-Wen Lin, Meng-Hsuan Cheng, Ya-Ting Lin, So-Yi Chang, Bo-Shiun Yan, Ching-Hua Kuo, Po-Liang Lu, Jann-Yuan Wang, and et al. 2019. "Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI" Journal of Clinical Medicine 8, no. 6: 812. https://doi.org/10.3390/jcm8060812

Lee, M.-R., Huang, H.-L., Lin, S.-W., Cheng, M.-H., Lin, Y.-T., Chang, S.-Y., Yan, B.-S., Kuo, C.-H., Lu, P.-L., Wang, J.-Y., & Chong, I.-W. (2019). Isoniazid Concentration and NAT2 Genotype Predict Risk of Systemic Drug Reactions during 3HP for LTBI. Journal of Clinical Medicine, 8(6), 812. https://doi.org/10.3390/jcm8060812